JP2015508824A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015508824A5 JP2015508824A5 JP2014560045A JP2014560045A JP2015508824A5 JP 2015508824 A5 JP2015508824 A5 JP 2015508824A5 JP 2014560045 A JP2014560045 A JP 2014560045A JP 2014560045 A JP2014560045 A JP 2014560045A JP 2015508824 A5 JP2015508824 A5 JP 2015508824A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- polyclonal igg
- mammal
- neuropathy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 52
- 239000008194 pharmaceutical composition Substances 0.000 claims description 46
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 38
- 241000124008 Mammalia Species 0.000 claims description 31
- 210000004116 schwann cell Anatomy 0.000 claims description 18
- 201000001119 neuropathy Diseases 0.000 claims description 17
- 230000007823 neuropathy Effects 0.000 claims description 17
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 12
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 12
- 230000037396 body weight Effects 0.000 claims description 12
- 230000003210 demyelinating effect Effects 0.000 claims description 12
- 208000014674 injury Diseases 0.000 claims description 8
- 230000008733 trauma Effects 0.000 claims description 8
- 102400000739 Corticotropin Human genes 0.000 claims description 6
- 101800000414 Corticotropin Proteins 0.000 claims description 6
- 108010072051 Glatiramer Acetate Proteins 0.000 claims description 6
- 102000014150 Interferons Human genes 0.000 claims description 6
- 108010050904 Interferons Proteins 0.000 claims description 6
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 claims description 6
- 239000003246 corticosteroid Substances 0.000 claims description 6
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical group C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims description 6
- 229960000258 corticotropin Drugs 0.000 claims description 6
- 229960003776 glatiramer acetate Drugs 0.000 claims description 6
- 229940079322 interferon Drugs 0.000 claims description 6
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 6
- 210000000578 peripheral nerve Anatomy 0.000 claims description 6
- 230000001737 promoting effect Effects 0.000 claims description 6
- 239000003053 toxin Substances 0.000 claims description 6
- 231100000765 toxin Toxicity 0.000 claims description 6
- 108700012359 toxins Proteins 0.000 claims description 6
- 101150028955 MBP gene Proteins 0.000 claims description 4
- 208000010886 Peripheral nerve injury Diseases 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- 230000023105 myelination Effects 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 210000002569 neuron Anatomy 0.000 claims description 3
- 206010061666 Autonomic neuropathy Diseases 0.000 claims description 2
- 102000006386 Myelin Proteins Human genes 0.000 claims description 2
- 108010083674 Myelin Proteins Proteins 0.000 claims description 2
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 claims description 2
- 210000003050 axon Anatomy 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 230000004069 differentiation Effects 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 210000005012 myelin Anatomy 0.000 claims description 2
- 230000001537 neural effect Effects 0.000 claims description 2
- 201000005572 sensory peripheral neuropathy Diseases 0.000 claims description 2
- 230000003827 upregulation Effects 0.000 claims description 2
- 238000001361 intraarterial administration Methods 0.000 claims 3
- 238000001990 intravenous administration Methods 0.000 claims 3
- 238000007920 subcutaneous administration Methods 0.000 claims 3
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 239000002158 endotoxin Substances 0.000 claims 1
- 239000001963 growth medium Substances 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 210000002856 peripheral neuron Anatomy 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 206010022031 Inherited neuropathies Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 206010061811 demyelinating polyneuropathy Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 206010065579 multifocal motor neuropathy Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261605117P | 2012-02-29 | 2012-02-29 | |
| US61/605,117 | 2012-02-29 | ||
| PCT/US2013/028350 WO2013130826A2 (en) | 2012-02-29 | 2013-02-28 | Igg stimulated remyelination of peripheral nerves |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017175330A Division JP6637934B2 (ja) | 2012-02-29 | 2017-09-13 | 末梢神経のＩｇＧ刺激性再ミエリン化法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015508824A JP2015508824A (ja) | 2015-03-23 |
| JP2015508824A5 true JP2015508824A5 (https=) | 2016-04-14 |
| JP6335800B2 JP6335800B2 (ja) | 2018-05-30 |
Family
ID=47884569
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014560045A Active JP6335800B2 (ja) | 2012-02-29 | 2013-02-28 | 末梢神経のＩｇＧ刺激性再ミエリン化法 |
| JP2017175330A Active JP6637934B2 (ja) | 2012-02-29 | 2017-09-13 | 末梢神経のＩｇＧ刺激性再ミエリン化法 |
| JP2019183415A Active JP6979990B2 (ja) | 2012-02-29 | 2019-10-04 | 末梢神経のＩｇＧ刺激性再ミエリン化法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017175330A Active JP6637934B2 (ja) | 2012-02-29 | 2017-09-13 | 末梢神経のＩｇＧ刺激性再ミエリン化法 |
| JP2019183415A Active JP6979990B2 (ja) | 2012-02-29 | 2019-10-04 | 末梢神経のＩｇＧ刺激性再ミエリン化法 |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US8986670B2 (https=) |
| EP (2) | EP3590960B1 (https=) |
| JP (3) | JP6335800B2 (https=) |
| KR (3) | KR102170615B1 (https=) |
| CN (4) | CN107551269A (https=) |
| AR (2) | AR090211A1 (https=) |
| AU (3) | AU2013203088B2 (https=) |
| BR (1) | BR112014021240A2 (https=) |
| DK (2) | DK2820042T3 (https=) |
| EA (2) | EA201892521A1 (https=) |
| ES (2) | ES2755056T3 (https=) |
| FI (1) | FI3590960T3 (https=) |
| HK (1) | HK1248534A1 (https=) |
| IL (3) | IL277103B2 (https=) |
| MX (2) | MX369444B (https=) |
| NZ (1) | NZ629867A (https=) |
| PL (2) | PL2820042T3 (https=) |
| PT (2) | PT3590960T (https=) |
| SG (1) | SG11201405302WA (https=) |
| TW (3) | TWI700297B (https=) |
| WO (1) | WO2013130826A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107551269A (zh) * | 2012-02-29 | 2018-01-09 | 百深公司 | 周围神经的IgG刺激髓鞘再生 |
| US9690975B2 (en) * | 2015-05-28 | 2017-06-27 | Axogen Corporation | Quantitative structural assay of a nerve graft |
| US11511136B2 (en) | 2017-11-17 | 2022-11-29 | The Research Foundation For The State University Of New York | Method for treating damaged peripheral nerves using x-ray microbeam irradiation |
| EP3908256A4 (en) * | 2019-01-07 | 2022-09-21 | Mallinckrodt Ard IP Unlimited Company | METHOD TO PROMOTE REMYELINATION |
| GB201907882D0 (en) | 2019-06-03 | 2019-07-17 | Cyprus Foundation For Muscular Dystrophy Res | Methods |
| EP4737584A1 (en) * | 2023-06-30 | 2026-05-06 | FUJIFILM Corporation | Method for evaluating intercellular interaction of neuroinflammation |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE348942B (https=) | 1970-06-02 | 1972-09-18 | Statens Bakteriologiska Labor | |
| DK166763C (da) | 1983-03-16 | 1993-07-12 | Immuno Ag | Immunoglobulin-g-holdig fraktion |
| AT376367B (de) | 1983-03-16 | 1984-11-12 | Immuno Ag | Verfahren zur herstellung von therapeutisch verabreichbaren, in endbehaeltern abgefuellten plasmaderivaten |
| EP0124506B1 (de) | 1983-05-02 | 1988-08-17 | IMMUNO Aktiengesellschaft für chemisch-medizinische Produkte | Verfahren zur Inaktivierung von vermehrungsfähigen Krankheitserregern |
| AT389815B (de) | 1984-03-09 | 1990-02-12 | Immuno Ag | Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten |
| AT390560B (de) | 1986-05-30 | 1990-05-25 | Immuno Ag | Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern |
| JP2871709B2 (ja) | 1988-11-21 | 1999-03-17 | 住友製薬株式会社 | 免疫グロブリンｇ結合活性を有する新規な蛋白質プロテインｈ、該蛋白質をコードする遺伝子及び該蛋白質の製造法 |
| US5177194A (en) | 1990-02-01 | 1993-01-05 | Baxter International, Inc. | Process for purifying immune serum globulins |
| CA2089582A1 (en) * | 1990-08-15 | 1992-02-16 | Richard P. Bunge | Autotransplantation of schwann cells to promote nervous system repair |
| AT402891B (de) | 1991-06-20 | 1997-09-25 | Immuno Ag | Verfahren zur herstellung eines inaktivierten blutproduktes |
| AU6653094A (en) | 1992-12-16 | 1994-07-04 | Immuno Aktiengesellschaft | Process for preparing a virus-safe biological composition |
| FR2706466B1 (fr) | 1993-06-14 | 1995-08-25 | Aetsrn | Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré. |
| HRP940645A2 (en) | 1993-10-06 | 1996-12-31 | Immuno Ag | Process for virus deactivation in the presence of polyalkylene glycol and the pharmaceutical preparation thus obtained |
| TW491855B (en) | 1996-08-07 | 2002-06-21 | Csl Ltd | Purification of immunoglobulins |
| US5886154A (en) | 1997-06-20 | 1999-03-23 | Lebing; Wytold R. | Chromatographic method for high yield purification and viral inactivation of antibodies |
| IL140155A (en) | 1998-06-09 | 2005-12-18 | Statens Seruminstitut | Process for producing immunoglobulins for intravenous administration and other immunoglobulin products |
| SE0001128D0 (sv) | 2000-03-30 | 2000-03-30 | Amersham Pharm Biotech Ab | A method of producing IgG |
| IL152738A0 (en) * | 2000-05-10 | 2003-06-24 | Mayo Foundation | Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system |
| FR2824568B1 (fr) | 2001-05-11 | 2004-04-09 | Lab Francais Du Fractionnement | Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique |
| JP2003070465A (ja) * | 2001-08-31 | 2003-03-11 | Keio Gijuku | シュワン細胞の培養方法 |
| CA2514117A1 (en) | 2003-01-24 | 2004-08-12 | Elan Pharmaceuticals, Inc. | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents |
| US20070244305A1 (en) | 2004-01-30 | 2007-10-18 | Suomen Punainen Risti Veripalvelu | Process for The Manufacture of Virus Safe Immunoglobulin |
| CA2557229C (en) | 2004-02-27 | 2012-07-10 | Octapharma Ag | A method of providing a purified, virus safe antibody preparation |
| SG178744A1 (en) * | 2007-02-02 | 2012-03-29 | Biogen Idec Inc | Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation |
| US7854703B2 (en) | 2007-09-25 | 2010-12-21 | Intel Corporation | Peripheral neuropathy detection |
| CA2643496C (en) | 2008-11-06 | 2015-02-03 | Michael Fehlings | The therapeutic use of igg as a neuroprotective agent |
| CN102021140B (zh) * | 2009-09-18 | 2013-04-24 | 上海市第一人民医院 | 一种分离、纯化许旺细胞的方法 |
| CN107551269A (zh) * | 2012-02-29 | 2018-01-09 | 百深公司 | 周围神经的IgG刺激髓鞘再生 |
-
2013
- 2013-02-28 CN CN201710896364.6A patent/CN107551269A/zh active Pending
- 2013-02-28 DK DK13709675T patent/DK2820042T3/da active
- 2013-02-28 US US13/781,283 patent/US8986670B2/en active Active
- 2013-02-28 CN CN201910008205.7A patent/CN109966488A/zh active Pending
- 2013-02-28 PL PL13709675T patent/PL2820042T3/pl unknown
- 2013-02-28 EA EA201892521A patent/EA201892521A1/ru unknown
- 2013-02-28 CN CN201910611688.XA patent/CN110343171A/zh active Pending
- 2013-02-28 PL PL19180237.0T patent/PL3590960T3/pl unknown
- 2013-02-28 DK DK19180237.0T patent/DK3590960T3/da active
- 2013-02-28 EP EP19180237.0A patent/EP3590960B1/en active Active
- 2013-02-28 IL IL277103A patent/IL277103B2/en unknown
- 2013-02-28 NZ NZ629867A patent/NZ629867A/en unknown
- 2013-02-28 FI FIEP19180237.0T patent/FI3590960T3/fi active
- 2013-02-28 EP EP13709675.6A patent/EP2820042B1/en active Active
- 2013-02-28 PT PT191802370T patent/PT3590960T/pt unknown
- 2013-02-28 ES ES13709675T patent/ES2755056T3/es active Active
- 2013-02-28 KR KR1020147027130A patent/KR102170615B1/ko active Active
- 2013-02-28 IL IL274512A patent/IL274512B2/en unknown
- 2013-02-28 KR KR1020207030277A patent/KR20200126005A/ko not_active Ceased
- 2013-02-28 EA EA201400966A patent/EA032000B1/ru not_active IP Right Cessation
- 2013-02-28 ES ES19180237T patent/ES2943585T3/es active Active
- 2013-02-28 JP JP2014560045A patent/JP6335800B2/ja active Active
- 2013-02-28 WO PCT/US2013/028350 patent/WO2013130826A2/en not_active Ceased
- 2013-02-28 BR BR112014021240A patent/BR112014021240A2/pt not_active Application Discontinuation
- 2013-02-28 SG SG11201405302WA patent/SG11201405302WA/en unknown
- 2013-02-28 CN CN201380021280.8A patent/CN104302666A/zh active Pending
- 2013-02-28 KR KR1020227011045A patent/KR102673154B1/ko active Active
- 2013-02-28 PT PT137096756T patent/PT2820042T/pt unknown
- 2013-02-28 AU AU2013203088A patent/AU2013203088B2/en active Active
- 2013-02-28 MX MX2014010387A patent/MX369444B/es active IP Right Grant
- 2013-03-01 TW TW106122004A patent/TWI700297B/zh active
- 2013-03-01 TW TW102107471A patent/TWI632158B/zh active
- 2013-03-01 TW TW107124197A patent/TW201838654A/zh unknown
- 2013-03-01 AR ARP130100662A patent/AR090211A1/es not_active Application Discontinuation
-
2014
- 2014-08-26 IL IL234303A patent/IL234303B/en active IP Right Grant
- 2014-08-28 MX MX2019012496A patent/MX2019012496A/es unknown
-
2015
- 2015-02-18 US US14/625,542 patent/US9834593B2/en active Active
-
2016
- 2016-02-23 AU AU2016201137A patent/AU2016201137B2/en active Active
-
2017
- 2017-09-13 JP JP2017175330A patent/JP6637934B2/ja active Active
- 2017-10-30 US US15/798,313 patent/US10494418B2/en active Active
-
2018
- 2018-01-02 AU AU2018200026A patent/AU2018200026B2/en active Active
- 2018-06-25 HK HK18108139.5A patent/HK1248534A1/zh unknown
-
2019
- 2019-10-04 JP JP2019183415A patent/JP6979990B2/ja active Active
- 2019-10-18 US US16/657,920 patent/US20200216518A1/en not_active Abandoned
- 2019-11-28 AR ARP190103486A patent/AR117207A2/es unknown
-
2021
- 2021-06-14 US US17/347,380 patent/US20210300997A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240382436A1 (en) | Application of r-ketamine and salt thereof as pharmaceuticals | |
| JP2015508824A5 (https=) | ||
| Hayley et al. | Neuroplasticity and the next wave of antidepressant strategies | |
| JP6424210B2 (ja) | プールされた免疫グロブリンｇを用いたアルツハイマー病の亜集団の治療 | |
| Grimaldi et al. | A pilot study on the use of interferon beta-1a in early Alzheimer’s disease subjects | |
| Li et al. | Role of microglia/macrophage polarisation in intraocular diseases | |
| Lerner et al. | Neuropsychiatric toxicity associated with cytokine therapies | |
| JP2025510294A5 (https=) | ||
| RU2010142456A (ru) | Синергические комбинации 5'-метилтиоаденозина | |
| Luo et al. | Erythropoietin is a hypoxia inducible factor-induced protective molecule in experimental autoimmune neuritis | |
| Lim et al. | The cardiovascular effects of midazolam co-induction to propofol for induction in aged patients | |
| FI3590960T3 (fi) | Perifeeristen hermojen IgG-stimuloitu remyelinaatio | |
| JP2013543004A5 (https=) | ||
| JP2009524612A (ja) | 多発性硬化症を治療及び／又は予防するための方法、ならびに多発性硬化症の間欠的治療用及び／又は間欠的予防用の薬剤を製造するためのエリスロポエチンの使用 | |
| JP2018030847A (ja) | 速い用量調節の漸増投与レジメンを用いた、インターフェロンの筋肉内投与に伴うインフルエンザ様症状を軽減するための方法 | |
| Kim et al. | Recombinant human erythropoietin in amyotrophic lateral sclerosis: a pilot study of safety and feasibility | |
| JP2014530246A5 (https=) | ||
| Chavoshinezhad et al. | Intranasal interferon-beta as a promising alternative for the treatment of Alzheimer's disease | |
| Huang et al. | Autocrine protective mechanisms of human granulocyte colony-stimulating factor (G-CSF) on retinal ganglion cells after optic nerve crush | |
| CA3097989A1 (en) | Methods for improving frailty and aging | |
| Bali et al. | Discontinuing long-term iloprost treatment for Raynaud’s phenomenon and systemic sclerosis: a singlecenter, randomized, placebo-controlled, doubleblind study | |
| CA2831154A1 (en) | Use of pertussis toxin as a therapeutic agent | |
| Platten et al. | Anti-inflammatory strategies for the treatment of multiple sclerosis–tryptophan catabolites may hold the key | |
| EP2726078B1 (en) | Methods for treating immune-mediated diseases of the nervous system administering a compound comprising agents that inhibit prokineticin receptors activity | |
| BAUER et al. | Immune Mechanisms Affecting the Functioning of the Central Nervous System (CNS) |